Small-cell Lung Cancer Clinical Trial
Official title:
An Open-Label, Multicenter, Phase 2 Study of the Safety and Efficacy of KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer (SCLC)
Verified date | August 2023 |
Source | Kartos Therapeutics, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with relapsed or refractory small cell lung cancer. This study will be conducted in 2 parts. Part 1 will evaluate two treatment arms, each with a different KRT-232 dose. Part 2 will continue the evaluation of the selected treatment arms from Part 1.
Status | Terminated |
Enrollment | 3 |
Est. completion date | August 26, 2022 |
Est. primary completion date | August 26, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histologically or cytologically confirmed diagnosis of SCLC documented as TP53WT - Disease must be measurable per RECIST Version 1.1 - Evidence of radiographic progression during or after at least one prior platinum-containing therapy with no curative therapy available. Subjects who have received only one prior line of therapy must not be candidates for platinum-based regimens at relapse. - Subjects must have received a checkpoint inhibitor (PD-1 or PD-L1) unless contraindicated if checkpoint inhibitors are approved and available. - ECOG = 2 Exclusion Criteria: - Symptomatic or uncontrolled central nervous system (CNS) metastases. - Prior treatment with MDM2 inhibitors - Chemotherapy, immune therapy, cytokine therapy, or any investigational therapy within 14 days prior to the first dose of study treatment - Grade 2 or higher QTc prolongation (> 480 milliseconds per NCI-CTCAE criteria, version 5.0) - History of major organ transplant |
Country | Name | City | State |
---|---|---|---|
Australia | Flinders Medical Centre | Bedford Park | South Australia |
France | Edog - Ico - Ppds | Angers | Maine-et-Loire |
France | EDOG - Institut Bergonie - PPDS | Bordeaux | |
France | Hôpital Louis Pradel | Bron | Rhône |
France | CHU de Grenoble | Grenoble | |
France | Hospices Civils de Lyon | Lyon | Rhône |
France | Hopital Nord AP-HM | Marseille | |
France | Centre Hospitalier de Mulhouse - Hopital Emile Muller | Mulhouse | France/Haut-Rhin |
France | Hôpital de La Croix Rousse | Pierre-Bénite | Rhône |
Germany | Evangelische Lungenklinik Berlin | Berlin | |
Germany | Klinik für Kardiologie, Angiologie und Pneumologie | Esslingen am Neckar | Baden-Württemberg |
Germany | Lungenfachklinik Immenhausen | Immenhausen | Hessen |
Hungary | Bacs Kiskun Megyei Korhaz | Kecskemét | Bács-Kiskun |
Korea, Republic of | Chungbuk National University Hospital | Cheongju-si | Chungcheongbuk-do |
Korea, Republic of | CHA Bundang Medical Center, CHA University | Seongnam-si | Gyeonggido |
Spain | Hospital General Universitario de Alicante | Alicante | |
Spain | Hospital Universitario 12 de Octubre | Alicante | |
Spain | Hospital Universitario Vall d'Hebrón - PPDS | Barcelona | |
Spain | Clinica Universidad Navarra - Madrid | Madrid | |
Spain | Hospital Universitario La Paz | Madrid | |
Spain | Hospital Regional Universitario de Malaga - Hospital Civil | Málaga | |
Spain | Clinica Universidad Navarra | Pamplona | Navarra |
Spain | Hospital Universitario Virgen Macarena | Sevilla | |
Spain | Hospital Universitari i Politecnic La Fe de Valencia | Valencia | |
United States | Hematology Oncology Clinic | Baton Rouge | Louisiana |
United States | SCRI Tennessee Oncology Chattanooga | Chattanooga | Tennessee |
United States | University Hospitals Cleveland Medical Center | Cleveland | Ohio |
United States | Mark H Zangmeister Center - 3100 Plaza Properties Boulevard | Columbus | Ohio |
United States | Florida Cancer Specialists - 3840 Broadway | Fort Myers | Florida |
United States | Northwest Georgia Oncology Centers | Marietta | Georgia |
United States | SCRI Tennessee Oncology Nashville | Nashville | Tennessee |
United States | Florida Cancer Specialists - 560 Jackson St, Suite 220 | Saint Petersburg | Florida |
United States | Florida Cancer Specialists | West Palm Beach | Florida |
Lead Sponsor | Collaborator |
---|---|
Kartos Therapeutics, Inc. |
United States, Australia, France, Germany, Hungary, Korea, Republic of, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective response rate (ORR) of each arm | The proportion of subjects achieving partial response or better per RECIST 1.1 | 24 weeks | |
Secondary | Duration of response (DOR) of each arm | Time from initiation of response to disease progression or death | 1 year | |
Secondary | Progression-free survival (PFS) of each arm | Time from first dose to disease progression or death | 1 year | |
Secondary | Overall survival (OS) of each arm | Time from first dose to death | 1 year | |
Secondary | Disease control rate (DCR) of each arm | The proportion of subjects achieving stable disease or better per RECIST 1.1 | 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05552846 -
Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy
|
Phase 2 | |
Terminated |
NCT04022876 -
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
|
Phase 1 | |
Recruiting |
NCT06022757 -
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04923776 -
Liver Directed RT + Chemo-immunotherapy for ES-SCLC
|
Phase 2 | |
Recruiting |
NCT04168281 -
Watchful Observation of Patients With LD-SCLC Instead of the PCI
|
N/A | |
Completed |
NCT03239171 -
Bioinformation Therapy for Lung Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT06457906 -
SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC
|
Phase 3 | |
Recruiting |
NCT04539977 -
PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer
|
Phase 2 | |
Completed |
NCT03345485 -
Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06103682 -
LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)
|
N/A | |
Recruiting |
NCT04170946 -
Talazoparib and Thoracic RT for ES-SCLC
|
Phase 1 | |
Recruiting |
NCT03523234 -
Neoadjuvant Therapy Combined With Radical Surgery for the Treatment of Small Cell Lung Cancer (SCLC) in II and IIIA Stage
|
N/A | |
Recruiting |
NCT05620134 -
Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05578326 -
Study of Trilaciclib and Lurbinectidin
|
Phase 2 | |
Recruiting |
NCT06255197 -
Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
|
||
Terminated |
NCT04610658 -
Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
|
Phase 1 | |
Active, not recruiting |
NCT04116320 -
Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT05091567 -
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
|
Phase 3 | |
Terminated |
NCT04596033 -
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
|
Phase 1 |